...
首页> 外文期刊>ChemMedChem >8-Benzyltetrahydropyrazino[2,1-flpurinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases
【24h】

8-Benzyltetrahydropyrazino[2,1-flpurinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases

机译:8-苄基四氢吡嗪并[2,1-氟丁二酮:水溶性三环黄嘌呤衍生物作为神经退行性疾病的多靶点药物

获取原文
获取原文并翻译 | 示例
           

摘要

8-Benzyl-substituted tetrahydropyrazino[2,1-flpurinediones were designed as tricyclic xanthine derivatives containing a basic nitrogen atom in the tetrahydropyrazine ring to improve water solubility. A library of 69 derivatives was prepared and evaluated in radioligand binding studies at adenosine receptor (AR) subtypes and for their ability to inhibit monoamine oxidases (MAO). Potent dual-target-directed A,/A_(2A) adenosine receptor antagonists were identified. Several compounds showed triple-target inhibition; one of the best compounds was 8-(2,4-dichloro-5-fluorobenzyl)-1,3-dimethyl-6,7,8,9-tetra-hydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (72) (human AR: K,A, 217 nM, A_(2A) 233 nM; IC_(50) MAO-B: 508 nM). Dichlorinated compound 36 [8-(3,4-dichlorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione] was found to be the best triple-target drug in rat (K_i A1 351 nM, A_(2A) 322 nM; IC_(50) MAO-B: 260 nM), and may serve as a useful tool for preclinical proof-of-principle studies. Compounds that art at multiple targets relevant for symptomatic as well as disease-modifying treatment of neurodegenerative diseases are expected to show advantages over single-target therapeutics.
机译:8苄基取代的四氢吡嗪并[2,1-氟丁二酮被设计为在四氢吡嗪环中含有碱性氮原子的三环黄嘌呤衍生物,以提高水溶性。制备了69种衍生物的文库,并在放射性配体结合研究中评估了腺苷受体(AR)亚型及其抑制单胺氧化酶(MAO)的能力。确定了有效的双重目标指导的A,/ A_(2A)腺苷受体拮抗剂。几种化合物显示出三重靶标抑制作用。最好的化合物之一是8-(2,4-二氯-5-氟苄基)-1,3-二甲基-6,7,8,9-四氢吡嗪并[2,1-f]嘌呤-2,4( 1H,3H)-二酮(72)(人AR:K,A,217 nM,A_(2A)233 nM; IC_(50)MAO-B:508 nM)。二氯化化合物36 [8-(3,4-二氯苄基)-1,3-二甲基-6,7,8,9-四氢吡嗪并[2,1-f]嘌呤-2,4(1H,3H)-二酮]为被发现是大鼠中最好的三靶标药物(K_i A1 351 nM,A_(2A)322 nM; IC_(50)MAO-B:260 nM),并且可以用作临床前原理证明的有用工具学习。预期在与神经退行性疾病的症状以及疾病缓解治疗相关的多个靶标上起作用的化合物显示出优于单靶标治疗剂的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号